News

Phase 3 trials demonstrated that icotrokinra met all primary and co-primary endpoints, including PASI 90 and IGA 0/1 responses.

Explore innovative treatments for seborrheic dermatitis, including roflumilast foam, and learn about effective patient-centered care strategies.

HS management is shifting toward earlier diagnosis and intervention to prevent long-term scarring and disability.

In the latest Cutaneous Connection podcast episode, Renata Block, DMSc, MMS, PA-C, and Isabelle Thibau, MPH, discuss the National Eczema Association's EczemaWise app and how it can be used by both clinicians and patients.

Dermalogica's PRO Pen Microneedling System gains FDA clearance, revolutionizing non-invasive skin treatments with advanced technology and customizable options.

Discover the benefits of RetaXome therapy for sensitive skin and its potential in skin care routines.

The expanded voluntary recall is due to the potential microbial contamination of Burkholderia cepacia complex.

Amlitelimab shows promising phase 3 results in treating atopic dermatitis, achieving significant skin clearance and potential for infrequent dosing.

The new product expands Obagi Medical’s portfolio beyond skin care into injectables.

Alopecia areata treatment advances with targeted therapies, improving patient outcomes and access while addressing the emotional impact of hair loss.

This review of the latest dermatologic studies highlights new research on novel image fusion for tongue SCC, persistent nodules following HA fillers, rice bran extract for wound healing, and more.

Isotretinoin significantly reduces inflammatory cytokines IL-8, IL-36, and TWEAK in acne patients, promoting long-term acne remission and healing.

New insights reveal psoriasis patients' challenges with family planning and pregnancy, highlighting the need for better information and support from healthcare providers.

Phase 3 topline results reveal rocatinlimab's promising safety and efficacy for moderate to severe AD, targeting the OX40 receptor.

Forty percent of participants achieved at least a 75% reduction in facial vitiligo scores.

In part 3 of this Case-Based Roundtable supplement, Seemal Desai, MD, FAAD; Ted Lain, MD, MBA, FAAD; and Pearl Grimes, MD, FAAD, discuss real-world vitiligo scenarios, offering diagnostic insights, therapeutic strategies, and practical pearls from their own experiences.

Medicus Pharma has initiated a phase 2 trial in the UAE for a non-invasive BCC treatment, aiming to revolutionize skin cancer care.

LEO Pharma's delgocitinib cream for chronic hand eczema is now available to prescribe in the US.

Greater awareness of UV risks and stricter sun protection have contributed to declining invasive melanoma rates.

Novel formulations like retinal-infused exosomes represent an evolution rather than a replacement of retinoid therapy.

New findings reveal the effectiveness of corticosteroids and Janus kinase (JAK) inhibitors post noncultured epidermal suspension (NCES) transplantation for vitiligo, highlighting varied repigmentation responses.

In part 2 of this Case-Based Roundtable supplement, Seemal Desai, MD, FAAD; Ted Lain, MD, MBA, FAAD; and Pearl Grimes, MD, FAAD, discuss real-world vitiligo scenarios, offering diagnostic insights, therapeutic strategies, and practical pearls from their own experiences.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about Arcutis' sNDA for roflumilast in pediatric plaque psoriasis patients, Replimune's Type A meeting with the FDA on RP1, insights on deuruxolitinib for hair growth in alopecia, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Explore the potential of dupilumab for treating omalizumab-resistant chronic spontaneous urticaria, offering new hope for affected patients.

Explore how model-informed drug development shapes ligelizumab's journey in treating chronic spontaneous urticaria, despite its eventual discontinuation.

Explore how dermatology-focused global medical missions can move beyond short-term “voluntourism” by fostering sustainable, collaborative partnerships that prioritize education, capacity building, and alignment with host country needs.

The study found that 59% of patients achieved IGA treatment success, surpassing other topical therapies.